JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer

NCT06581380 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

394

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: JK-1201I
DRUG: Topotecan

Sponsor

JenKem Technology Co., Ltd.